Abstract

Male bone cancer (MaBC) is a clinically uncommon condition that accounts for about 1 of all cases of bone cancer. Yet, over the past few decades, MaBC has become more common. Age, black race, inherited mutations, liver cirrhosis, malformed testicles, family history of bone cancer, and age are risk factors for MaBC. The majority of mature MaBC cases come with painless lumps, and at the time of consultation, at least one lymph node is implicated in nearly half of the cases. MaBC is treated similarly to womanish bone cancer (FeBC), but this is largely because prospective research on MaBC cases are lacking. Surgery, adjuvant radiation, endocrine therapy, and chemotherapy are some of the treatment options. To perform clinical studies for MaBC or include MaBC cases in FeBC trials, ongoing transnational conflict is required. This will aid doctors in providing better care for MaBC clients.